ATLAB Pharma

ATLAB Pharma develops antibody-targeted radiotherapy for cancer treatment. Radioimmunotherapy is a tumor-specific delivery system using monoclonal antibodies conjugated to radioisotopes (radio-antibodies) to target radiation to cancer cells wherever they have disseminated in the body, thus expanding the well-proven efficacy of radiotherapy from localized tumors to metastatic cancers. ATLAB Pharma is at the forefront of developing safe and efficient radio-antibodies based on new generation therapeutic radioisotopes Lutetium-177 and Astatine-211. ATLAB Pharma lead drug candidate, ATL101, has been shown to have a favorable safety profile and anti-tumor activity in Phase I and Phase II clinical trials in patients with castrate-resistant prostate cancer.